CA2952336C - Thioureylene liquid compositions - Google Patents

Thioureylene liquid compositions Download PDF

Info

Publication number
CA2952336C
CA2952336C CA2952336A CA2952336A CA2952336C CA 2952336 C CA2952336 C CA 2952336C CA 2952336 A CA2952336 A CA 2952336A CA 2952336 A CA2952336 A CA 2952336A CA 2952336 C CA2952336 C CA 2952336C
Authority
CA
Canada
Prior art keywords
composition according
composition
group
gum
xanthan gum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2952336A
Other languages
English (en)
French (fr)
Other versions
CA2952336A1 (en
Inventor
Louise Reynolds
Manish UMRETHIA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Norbrook Laboratories Ltd
Original Assignee
Norbrook Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norbrook Laboratories Ltd filed Critical Norbrook Laboratories Ltd
Publication of CA2952336A1 publication Critical patent/CA2952336A1/en
Application granted granted Critical
Publication of CA2952336C publication Critical patent/CA2952336C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2952336A 2014-06-25 2015-06-23 Thioureylene liquid compositions Active CA2952336C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1411310.4 2014-06-25
GB1411310.4A GB2527555B (en) 2014-06-25 2014-06-25 Stable methimazole liquid compositions
PCT/GB2015/051824 WO2015198033A1 (en) 2014-06-25 2015-06-23 Thioureylene liquid compositions

Publications (2)

Publication Number Publication Date
CA2952336A1 CA2952336A1 (en) 2015-12-30
CA2952336C true CA2952336C (en) 2023-02-14

Family

ID=51410113

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2952336A Active CA2952336C (en) 2014-06-25 2015-06-23 Thioureylene liquid compositions

Country Status (19)

Country Link
US (6) US10045967B2 (https=)
EP (2) EP3160441B1 (https=)
JP (1) JP6799465B2 (https=)
AU (1) AU2015278962B2 (https=)
CA (1) CA2952336C (https=)
CY (2) CY1124535T1 (https=)
DK (2) DK3160441T3 (https=)
ES (2) ES2905083T3 (https=)
GB (1) GB2527555B (https=)
HR (2) HRP20220078T1 (https=)
HU (1) HUE056787T2 (https=)
LT (2) LT3160441T (https=)
NZ (1) NZ728018A (https=)
PL (2) PL3441063T3 (https=)
PT (2) PT3160441T (https=)
RS (2) RS62321B1 (https=)
SI (2) SI3441063T1 (https=)
SM (2) SMT202200043T1 (https=)
WO (1) WO2015198033A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2527555B (en) 2014-06-25 2018-09-19 Norbrook Lab Ltd Stable methimazole liquid compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4096174A (en) * 1977-07-01 1978-06-20 American Cyanamid Company Anionic naphthalene thioureido-diphenyloxides
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US5310742A (en) * 1992-11-30 1994-05-10 Elias Alan N Uses for thioureylenes
CA2407335C (en) * 2000-05-03 2010-08-03 Joe D'silva Process and device for producing liquid dosage formulations
US20050158367A1 (en) * 2004-01-16 2005-07-21 The Procter & Gamble Company Liquid compositions comprising one or more medicaments
AU2007207991B2 (en) * 2006-01-26 2011-08-04 Hill's Pet Nutrition, Inc. Methods and compositions for treating feline hyperthyroidism
GB2438287A (en) * 2006-05-19 2007-11-21 Norbrook Lab Ltd Stable aqueous suspension
US20100286154A1 (en) * 2007-11-15 2010-11-11 Susanne Christine Wieland-Berghausen Antihelmintic paste
GB2527555B (en) 2014-06-25 2018-09-19 Norbrook Lab Ltd Stable methimazole liquid compositions

Also Published As

Publication number Publication date
WO2015198033A1 (en) 2015-12-30
RS62850B1 (sr) 2022-02-28
LT3160441T (lt) 2022-02-25
CY1124961T1 (el) 2023-01-05
PL3160441T3 (pl) 2022-02-28
NZ728018A (en) 2019-06-28
ES2884573T3 (es) 2021-12-10
GB201411310D0 (en) 2014-08-06
JP2017519029A (ja) 2017-07-13
HRP20211354T1 (hr) 2021-11-26
US20180318262A1 (en) 2018-11-08
US20200405690A1 (en) 2020-12-31
SMT202200043T1 (it) 2022-03-21
EP3441063A1 (en) 2019-02-13
ES2905083T3 (es) 2022-04-19
HRP20220078T1 (hr) 2022-04-15
HRP20211354T8 (hr) 2022-03-04
US20210361623A1 (en) 2021-11-25
US12171749B2 (en) 2024-12-24
EP3441063B1 (en) 2021-07-21
US10045967B2 (en) 2018-08-14
GB2527555B (en) 2018-09-19
DK3441063T3 (da) 2021-08-30
SMT202100487T1 (it) 2021-09-14
SI3160441T1 (sl) 2022-04-29
SI3441063T1 (sl) 2021-12-31
RS62321B1 (sr) 2021-10-29
EP3160441B1 (en) 2022-01-12
US20250064785A1 (en) 2025-02-27
LT3441063T (lt) 2021-10-11
US20170135987A1 (en) 2017-05-18
JP6799465B2 (ja) 2020-12-16
PL3441063T3 (pl) 2021-12-27
GB2527555A (en) 2015-12-30
CA2952336A1 (en) 2015-12-30
AU2015278962B2 (en) 2019-07-04
HUE056787T2 (hu) 2022-03-28
AU2015278962A1 (en) 2016-12-22
PT3160441T (pt) 2022-01-28
US11123327B2 (en) 2021-09-21
EP3160441A1 (en) 2017-05-03
US20230404978A1 (en) 2023-12-21
CY1124535T1 (el) 2022-07-22
PT3441063T (pt) 2021-08-31
US11738005B2 (en) 2023-08-29
DK3160441T3 (da) 2022-01-31

Similar Documents

Publication Publication Date Title
JP6448001B2 (ja) 液体配合剤
KR102593667B1 (ko) 5-콜레스텐-3, 25-디올, 3-술페이트 (25hc3s) 또는 이의 약학적으로 허용 가능한 염, 및 적어도 하나의 시클릭 올리고당을 포함하는 조성물
US20130095146A1 (en) Ciclesonide containing aqueous pharmaceutical composition
US20250064785A1 (en) Thioureylene liquid compositions
US20240374516A1 (en) Ready to use oral pharmaceutical suspension of dasatinib
MX2014010274A (es) Composiciones de liberacion controlada y metodos para su uso.
EA022936B1 (ru) Стабильные водосодержащие препараты, включающие плохо растворимые в воде активные компоненты
US11576929B2 (en) Composition for inflammatory gastrointestinal disorders
EP3402526B1 (en) New improved composition comprising at least one cadotril
TWI920454B (zh) 包含5-膽甾烯-3,25-二醇3-硫酸酯(25hc3s)或其醫藥上可接受之鹽及至少一種環狀寡醣的組成物,以及使用彼等之方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200611

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250613

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250613

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20260205

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260205

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260212